Xeris Biopharma Holdings (XERS) Amortizatization of Intangibles (2020 - 2024)
Xeris Biopharma Holdings (XERS) posted Amortizatization of Intangibles of $73000.0 for Q4 2024, down 61.98% on a QoQ basis from $192000.0 in Q3 2024, and down 50.0% year-over-year from $146000.0 in Q1 2024.
Xeris Biopharma Holdings (XERS) Amortizatization of Intangibles (2020 - 2024) Analysis & Trends
Xeris Biopharma Holdings' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $73000.0 for Q4 2024.
- Quarterly Amortizatization of Intangibles fell 50.0% year-over-year to $73000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $73000.0 (down 91.1% YoY) and the FY2024 annual result came in at $747000.0, down 40.86% from the prior year.
- Amortizatization of Intangibles was $73000.0 for Q4 2024 at Xeris Biopharma Holdings, down from $192000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $430000.0 in Q2 2023 and bottomed at -$154000.0 in Q1 2021.
- A 5-year average of $75058.8 and a median of -$19000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles jumped 1705.26% — and 2024, when it slumped 51.83%.
- Xeris Biopharma Holdings' Amortizatization of Intangibles stood at -$137000.0 in 2020, then soared by 56.2% to -$60000.0 in 2021, then soared by 40.0% to -$36000.0 in 2022, then surged by 505.56% to $146000.0 in 2023, then plunged by 50.0% to $73000.0 in 2024.
- Business Quant data shows XERS's Amortizatization of Intangibles at $73000.0 in Q4 2024, $192000.0 in Q3 2024, and $298000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Xeris Biopharma Holdings | 1.41 Bn | 1.30 Bn | 72.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 73,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Sep 30, 2024 | 192,000.00 |
| Sep 30, 2024 | 192,000.00 |
| Jun 30, 2024 | 298,000.00 |
| Jun 30, 2024 | 298,000.00 |
| Mar 31, 2024 | 184,000.00 |
| Mar 31, 2024 | 184,000.00 |
| Dec 31, 2023 | 146,000.00 |
| Dec 31, 2023 | 146,000.00 |
| Sep 30, 2023 | 305,000.00 |
| Sep 30, 2023 | 305,000.00 |
| Jun 30, 2023 | 430,000.00 |
| Jun 30, 2023 | 430,000.00 |
| Mar 31, 2023 | 382,000.00 |
| Mar 31, 2023 | 382,000.00 |
| Dec 31, 2022 | -36,000.00 |
| Dec 31, 2022 | -36,000.00 |
| Sep 30, 2022 | -19,000.00 |
| Sep 30, 2022 | -19,000.00 |